The second pitch session at #DemoDay featured presentations by cutting-edge startups, from Fragile X treatment to virtual reality for neuro-rehab. 🧠
Congrats to @A4i_me, Nospharma, Lasso Informatics, @physiobiometric, Neuro Solutions Group, @perceiv_ai and @XRTherapeutics! ✨
Discover the story of @perceiv_ai, a bold Montreal-based startup leveraging artificial intelligence to predict disease progression.
💡Imagine what your company could achieve with a partner like CQDM. Read more here: https://t.co/GDAZPFhh4t
@perceiv_ai, une startup basée à Montréal, a développé une plateforme qui utilise l’intelligence artificielle pour anticiper les effets des traitements contre des maladies telles que la maladie d’Alzheimer. https://t.co/dkHADAx49P
🤝 StartUp Health co @perceiv_ai announced a strategic partnership with @alleolabs to help select the most optimal patients for Alleo's upcoming clinical trials of ALO-001 for treating Parkinson’s and Alzheimer’s disease. https://t.co/1iN7jyybYp
In this StartUp Health Studio interview, Dr. Christian Dansereau shares how his AI-driven precision medicine company, @perceiv_ai, is developing a multimodal prognostic platform to forecast disease progression in age-related disorders. https://t.co/rZH9wV8SWi
Great start of 2024! 🎉 At
@perceiv_ai we are excited to announce a new partnership with @alleolabs to de-risk and support their clinical trials of ALO-001, a potential first-in-class deubiquitinating enzyme inhibitor for treating Parkinson’s and Alzheimer’s disease.
This week’s podcast features two #HealthTransformers—from @pearsuiteinc and @perceiv_ai—who are passionate about helping seniors thrive as they age, from using AI to predict Alzheimer's earlier to empowering front-line community health workers. https://t.co/hBSXGzrIuC
#HealthTransformer@chrisdansereau of @perceiv_ai joined us in the #StartUpHealth Studio @ #HLTH203 to talk about how his company optimizes & de-risks clinical trials for degenerative brain disorders, as well as empowers earlier patient diagnoses & interventions in the clinic.
A big milestone in #Alzheimer's treatment: FDA approves #Leqembi as the 1st disease-modifying therapy for AD, offering new hope to patients & families. @perceiv is working toward a risk predictor of AD's progression that can help better manage patients. https://t.co/uZHYJNnLMg
Excited to present new work at #ADPD2023 !
1) Results of a Pan-Canadian survey in partnership with Roche on acceptance of prognosis clinical decision support tools PCPs treating AD (Poster 1054)
2)Mitigating loss of statistical power due to outcome imbalance in AD (Poster 0329).